TY - JOUR
T1 - Optimal management of metastatic castration-resistant prostate cancer
T2 - highlights from a European Expert Consensus Panel
AU - Fitzpatrick, John M
AU - Bellmunt, Joaquim
AU - Fizazi, Karim
AU - Heidenreich, Axel
AU - Sternberg, Cora N
AU - Tombal, Bertrand
AU - Alcaraz, Antonio
AU - Bahl, Amit
AU - Bracarda, Sergio
AU - Di Lorenzo, Giuseppe
AU - Efstathiou, Eleni
AU - Finn, Stephen P
AU - Fosså, Sophie
AU - Gillessen, Silke
AU - Kellokumpu-Lehtinen, Pirkko-Liisa
AU - Lecouvet, Frédéric E
AU - Oudard, Stephane
AU - de Reijke, Theo M
AU - Robson, Craig N
AU - De Santis, Maria
AU - Seruga, Bostjan
AU - de Wit, Ronald
N1 - Copyright © 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
PY - 2014/6
Y1 - 2014/6
N2 - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.
AB - The exponential growth of novel therapies for the treatment of metastatic castration-resistant prostate cancer (mCRPC) over the last decade has created an acute need for education and guidance of clinicians regarding optimal strategies for patient management. A multidisciplinary panel of 21 European experts in mCRPC assembled for comprehensive discussion and consensus development, seeking to move the field forward and provide guidance and perspectives on optimal selection and sequencing of therapeutic agents and monitoring of response to treatment and disease progression. A total of 110 clinically-relevant questions were addressed and a modified Delphi method was utilised to obtain a consensus. The panel reached a consensus on several important issues, providing recommendations on appropriate phase III clinical trial end-points and optimal strategies for imaging and monitoring of bone metastases. Guidance regarding selection and sequencing of therapy in patients with newly diagnosed or progressive mCRPC is emphasised, including the use of novel bone-targeted agents, chemotherapy, androgen receptor pathway-targeted agents and immunotherapy. The impact of drug resistance and prostate-specific antigen flare on treatment decisions was also addressed. Ultimately, individualised therapy for patients with mCRPC is dependent on continued refinement of clinical decision-making based on patient and disease characteristics. This consensus statement offers clinicians expert guidance on the implementation of recent advances to improve patient outcome, focusing on the future of prostate cancer care.
KW - Androgen Receptor Antagonists/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
KW - Bone Density Conservation Agents/therapeutic use
KW - Clinical Trials as Topic
KW - Combined Modality Therapy/methods
KW - Diagnostic Imaging/methods
KW - Disease Progression
KW - Drug Resistance, Neoplasm
KW - Humans
KW - Immunotherapy/methods
KW - Male
KW - Prostatic Neoplasms, Castration-Resistant/diagnosis
KW - Treatment Outcome
U2 - 10.1016/j.ejca.2014.03.010
DO - 10.1016/j.ejca.2014.03.010
M3 - Article
C2 - 24703899
SN - 0959-8049
VL - 50
SP - 1617
EP - 1627
JO - European journal of cancer (Oxford, England : 1990)
JF - European journal of cancer (Oxford, England : 1990)
IS - 9
ER -
